EP4 receptor as a new target for bronchodilator therapy

Thorax

Volumn 66, Issue 12, 2011, Pages 1029-1035

  Buckley, James ^a   Birrell, Mark A ^a   Maher, Sarah A ^a   Nials, Anthony T ^b   Clarke, Deborah L ^a   Belvisi, Maria G ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (1 HYDROXYHEXYL)PHENYL] 5 OXOCYCLOPENTANEHEPTANOIC ACID; ONO AE 1 259; ONO AE 1 329; ONO AE 248; ONO D 1 004; PAPAVERINE; PROSTAGLANDIN E RECEPTOR 1; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; 4 (4 CYANO 2 (2 (4 FLUORONAPHTHALEN 1 YL)PROPIONYLAMINO)PHENYL)BUTYRIC ACID; 4-(4-CYANO-2-(2-(4-FLUORONAPHTHALEN-1-YL)PROPIONYLAMINO)PHENYL)BUTYRIC ACID; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 6-ISOPROPOXY-9-OXOXANTHENE-2-CARBOXYLIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 9 DEOXY 9 CHLORO 15 DEOXY 16 HYDROXY 17,17 TRIMETHYLENE 19,20 DIDEHYDROPROSTAGLANDIN E2; 9-DEOXY-9-CHLORO-15-DEOXY-16-HYDROXY-17,17-TRIMETHYLENE-19,20-DIDEHYDROPROSTAGLANDIN E2; ARYLBUTYRIC ACID DERIVATIVE; BRONCHODILATING AGENT; DRUG DERIVATIVE; ETHER DERIVATIVE; HYDRAZINE DERIVATIVE; NAPHTHALENE DERIVATIVE; ONO AE1 329; ONO DI 004; ONO-AE1-329; ONO-DI-004; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTANOIC ACID DERIVATIVE; XANTHONE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BRONCHODILATATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; GUINEA PIG; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SMOOTH MUSCLE RELAXATION; TRACHEA; ANIMAL; ASTHMA; C57BL MOUSE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DRUG POTENTIATION; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT;

ALPROSTADIL; ANIMALS; ASTHMA; BRONCHODILATOR AGENTS; DINOPROSTONE; GUINEA PIGS; HUMANS; HYDRAZINES; MACACA FASCICULARIS; METHYL ETHERS; MICE; MICE, INBRED C57BL; NAPHTHALENES; PHENYLBUTYRATES; PROSTANOIC ACIDS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; REGRESSION ANALYSIS; SPECIES SPECIFICITY; TRACHEA; XANTHONES;

EID: 81555216781     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2010.158568     Document Type: Article

References (35)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55. (Pubitemid 47403272)
2. Lemanske RF Jr, Busse WW. 6. Asthma. J Allergy Clin Immunol 2003;111:S502-9.
3. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008;31:143-78.
4. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26. (Pubitemid 43265239)
5. Kawakami Y, Uchiyama K, Irie T, et al. Evaluation of aerosols of prostaglandins E1 and E2 as bronchodilators. Eur J Clin Pharmacol 1973;6:127-32.
6. Seth RV, Clarke VS, Lewis RA, et al. Effect of propranolol on the airway response to prostaglandin E2 in normal man. Br J Clin Pharmacol 1981;12:731-5. (Pubitemid 11027991)
7. Walters EH, Bevan M, Davies BH. Interactions between response to inhaled prostaglandin E2 and chronic beta-adrenergic agonist treatment. Thorax 1982;37:430-7. (Pubitemid 12090128)
8. Costello JF, Dunlop LS, Gardiner PJ. Characteristics of prostaglandin induced cough in man. Br J Clin Pharmacol 1985;20:355-9. (Pubitemid 16236892)
9. Pavord ID, Wong CS, Williams J, et al. Effect of inhaled prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 1993;148:87-90. (Pubitemid 23187223)
10. Melillo E, Woolley KL, Manning PJ, et al. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994;149:1138-41. (Pubitemid 24147051)
11. Gauvreau GM, Watson RM, O'Byrne PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1999;159:31-6. (Pubitemid 29036499)
12. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994;46:205-29. (Pubitemid 24185151)
13. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev 1999;79:1193-226. (Pubitemid 29473315)
14. Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-90. (Pubitemid 32385902)
15. Tsuboi K, Sugimoto Y, Ichikawa A. Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat 2002;68-69:535-56. (Pubitemid 35247419)
16. 2-receptor agonist. Cardiovasc Drug Rev 1993;11:165-79.
17. Norel X, Walch L, Labat C, et al. Prostanoid receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol 1999;126:867-72. (Pubitemid 29103702)
18. Sheller JR, Mitchell D, Meyrick B, et al. EP(2) receptor mediates bronchodilation by PGE(2) in mice. J Appl Physiol 2000;88:2214-18. (Pubitemid 30453930)
19. Fortner CN, Breyer RM, Paul RJ. EP2 receptors mediate airway relaxation to substance P, ATP, and PGE2. Am J Physiol Lung Cell Mol Physiol 2001;281:L469-74.
20. Birrell MA, De Alba J, Catley MC, et al. Liver X receptor agonists increase airway reactivity in a model of asthma via increasing airway smooth muscle growth. J Immunol 2008;181:4265-71.
21. Gaddum JH. Theories of drug antagonism. Pharmacol Rev 1957;9:211-18.
22. Kiriyama M, Ushikubi F, Kobayashi T, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997;122:217-24. (Pubitemid 27397191)
23. Boie Y, Stocco R, Sawyer N, et al. Molecular cloning and characterisation of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol 1997;304:227-41. (Pubitemid 28022647)
24. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000;1483:285-93. (Pubitemid 30029060)
25. Wilson RJ, Giblin GM, Roomans S, et al. GW627368X ((N-{2-[4-(4, 9-diethoxy-1-oxo-1, 3-dihydro-2H-benzo [f] isoindol-2-yl) phenyl] acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist. Br J Pharmacol 2006;148:326-9.
26. Kabashima K, Saji T, Murata T, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest 2002;109:883-93. (Pubitemid 34275109)
27. Bouyssou T, Casarosa P, Naline E, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010;334:53-62.
28. Main IH. The inhibitory actions of prostaglandins on respiratory smooth muscle. Br J Pharmacol Chemother 1964;22:511-19.
29. Sweatman WJ, Collier HO. Effect of prostaglandins on human bronchial smooth muscle. Nature 1968;217:69.
30. 2 on airway tone. Am J Physiol Lung Cell Mol Physiol 2000;284:L599-606.
31. Maher SA, Birrell MA, Belvisi MG. Prostaglandin E2 mediates cough via the EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med 2009;180:923-8.
32. Lydford SJ, McKechnie K. Characterization of the prostaglandin E2 sensitive (EP)-receptor in the rat isolated trachea. Br J Pharmacol 1994;112:133-6.
33. Harmar AJ, Hills RA, Rosser EM, et al. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels. Nucl Acids Res 2009;37(Database issue):D680-5.
34. Suzawa T, Miyaura C, Inada M, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000;141:1554-9. (Pubitemid 32269125)
35. Stillman BA, Breyer MD, Breyer RM. Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol 1999;56:545-51. (Pubitemid 29406881)